General Information


DRACP ID  DRACP04016

Peptide Name  

Sequence  EMTWEEWEKKIEEYIKKIEEILKKSQNQQIDLGSGX

Sequence Length  36

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antiviral



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  C16

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C191H301N47O61S

Absent amino acids  ACFHPRV

Common amino acids  E

Mass  499830

Pl  4.41

Basic residues  6

Acidic residues  9

Hydrophobic residues  9

Net charge  -3

Boman Index  -8594

Hydrophobicity  -119.72

Aliphatic Index  75.83

Half Life 
  /

Extinction Coefficient cystines  12490

Absorbance 280nm  356.86

Polar residues  7

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 30901967

Title  A Peptide-Based HIV-1 Fusion Inhibitor With Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life

Doi Not available

Year  2019

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  15605

DRACP is developed by Dr.Zheng's team.